Dare Bioscience Inc reports results for the quarter ended in June - Earnings Summary

Dare Bioscience

13/08/2024 01:51

* Dare Bioscience Inc  DARE.OQ  reported a quarterly
adjusted loss
of 88 cents​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of $-1.20.  The mean expectation of four analysts for the
quarter was for breakeven results per share. Wall Street
expected results to range from -84 cents to $1.92 per share.
    * Revenue was $22.44 million​; analysts expected $5.89
million. 
    * Dare Bioscience Inc's reported EPS for the quarter was
$1.52​.
    * The company reported quarterly net income of $12.91
million.
    * Dare Bioscience Inc shares had fallen by 15.9% this
quarter and
lost 8.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 100%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Dare Bioscience
Inc is $48.00 
This summary was machine generated from LSEG data August 13 at
12:51 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      0.00           -0.88          Missed
 Mar. 31 2024      -0.72          -0.84          Missed
 Dec. 31 2023      -1.18          -0.72          Beat
 Sep. 30 2023      -1.18          -1.08          Beat